Parexel sees revenue and income growth in fiscal Q4 but margins slide

- Last updated on GMT

Related tags: Revenue, Income

Parexel, Q4, income
US CRO Parexel saw revenue and income growth in fiscal Q4 but margins shrank in the firm’s clinical research and eClinical business.

New revenue for the three months to June 30 increased by 26 per cent to $392m (EUR318m), with the contribution from clinical research services (CRS) climbing 13 per cent to $292m and that from Parexel’s consulting business growing 41 per cent to $49.7m.

Perceptive informatics – Parexel’s eClinical services unit – generated revenue of $50m from $42.4m in comparable quarter last year. Overall net income was $17.7m, up from a net loss of $1.5m last year.

The firm also saw a significant increase in bookings in the final three months of its fiscal year with new business wins of $601.9m giving it a book-to-bill (B2B) ratio of 1.53 and generating a backlog of approximately $4.4 bn.

Call today

Parexel will hold its earning call later today and will probably have to field questions about its gross margin - which declined from 31.4 per cent to 28.7 per cent.

Similarly the CRO can expect to be quizzed about margins in its eClinical and clinical business, both of which declined in developments that were not missed by analysts.

John Kreger from William Blair & Company said: “While revenues were better than our model in the quarter and bookings came in line with the range communicated during the late-May investor day, margins took a bigger step backward from what we expected and were down more than 160 basis points sequentially​.”

We maintain our Outperform rating at this time, but caution that bottom-line results could continue to be volatile as management strives to manage margins in light of the surprising degree of bookings growth of late.

Tim Evans from Wells Fargo Securities expressed similar sentiments.

Margins in both CRS and Perceptive were weak, though reasons were not provided in the press release​” he said, adding that “While the backlog conversion story is clearly playing out in the revenue growth margins are not following along, probably because of hiring after last quarter's 2.2 B2B and this quarter's 1.5 B2B​.”

Related news

Show more

Related products

show more

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Governing and Maintaining Clinical Data Standards

Governing and Maintaining Clinical Data Standards

Veeva | 10-May-2022 | Technical / White Paper

Investing in data standards plays a huge role in improving the quality of clinical studies. But often, people don’t use the standards correctly, there...

What the Best Clinical Study Build Pros Do

What the Best Clinical Study Build Pros Do

Formedix | 09-May-2022 | Technical / White Paper

Getting your clinical study designed and built ready for data collection takes A LOT of work and expertise… you've got to do all your CRF designs;...

What should a clinical metadata repository do?

What should a clinical metadata repository do?

Formedix | 18-Apr-2022 | Technical / White Paper

Choosing a clinical metadata repository (MDR) software can be a tough task as the capabilities and features of your chosen MDR could make or break your...

Related suppliers

Follow us


View more